| Name
|
[Tyr1]-MIF-1
|
| Other Name
|
MIF1 Tyr
|
| Sequence (Single letter abbreviations)
|
YPLG-NH2
|
| Sequence（Three letter abbreviations）
|
{TYR}{PRO}{LEU}{GLY}-NH2
|
| C-port
|
NH2
|
| Basic description
|
Tyr-MIF-1, an endogenous neuropeptides with opiate modulating and other CNS effects, can serve as a precursor of MIF-1 in brain mitochondria. Levels of the new tetrapeptide Tyr-MIF-1 are er in some parts of the brain than in others and can be altered by neuroendocrine manipulations raises the possibility that Tyr-MIF-1 may affect CNS functions regardless of any effects on MSH release.
|
| Solubility
|
Soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weight out a smaller portion of the contents.
|
| The molecular weight
|
447.530
|
| Chemical formula
|
C22H33N5O5
|
| The purity
|
> 95%
|
| Storage conditions
|
Storage at -20°C. Keep tightly closed.
|
| Annotation
|
Novel brain peptide.
|
| Documents
|
|
| Figures
|
|
| Reference
|
Watanabe H, et al. A Tyr-W-MIF-1 analog containing D-Pro2 acts as a selective mu2-opioid receptor antagonist in the mouse. J. Pharmacol. Exp. Ther. Mar 2005; 312(3):1075-81.
|
[Tyr1]-MIF-1
